Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injuryMelanie Deutsch, George Miller, Christopher S. Graffeo et al.|Cell Death and Disease|2015Cited by 129
Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical OptionsEmmanouil Koullias, Anastasia Thanopoulou, Maria Papavdi et al.|Cureus|2025Cited by 6
Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes MellitusEmmanouil Koullias, John Koskinas, P.S. Zoumpoulis et al.|Cureus|2024Cited by 4
ContributorsAlexander Abdurakhmanov, Anna Dubaniewicz, Mahmoud Abu‐Shakra et al.|Elsevier eBooks|2015Cited by 0